Evolução de pacientes com AIDS pós cART: Evolução clínica e laboratorial de pacientes com AIDS após 48 semanas de tratamento antirretroviral

• Autor(a) principal: Fukumoto, Ana Esther Carvalho Gomes [UNESP]
• Data de Publicação: 2013
• Outros Autores: Oliveira, Cristiano Claudino [UNESP], Tasca, Karen Ingrid [UNESP], Souza, Lenice do Rosario de [UNESP]
• Tipo de documento: Artigo
• Idioma: eng; por
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1590/S0036-46652013000400008; http://hdl.handle.net/11449/75833
• topic: Antiretroviral therapy; CD4+ T lymphocyte count; HIV/AIDS; Viral load of HIV; nonnucleoside reverse transcriptase inhibitor; proteinase inhibitor; RNA directed DNA polymerase inhibitor; virus RNA; adult; aged; blood analysis; CD4 lymphocyte count; clinical evaluation; drug response; female; highly active antiretroviral therapy; human; Human immunodeficiency virus 1; Human immunodeficiency virus 1 infection; laboratory test; major clinical study; male; medical record review; molecular evolution; treatment duration; treatment outcome; viremia; virus load

Combination Antiretroviral Therapy (cART) aims to inhibit viral replication, delay immunodeficiency progression and improve survival in AIDS patients. The objective of this study was to compare two different schemes of cART, based on plasma viral load (VL) and CD4+ T lymphocyte count, during 48 weeks of treatment. For this purpose, 472 medical charts of a Specialized Outpatient Service were reviewed from 1998 to 2005. Out of these, 58 AIDS patients who had received a triple drug scheme as the initial treatment were included in the study and two groups were formed: Group 1 (G1): 47 individuals treated with two nucleoside reverse-transcriptase inhibitors (NRTI) and one non-nucleoside reverse-transcriptase inhibitor; Group 2 (G2): 11 patients treated with two NRTI and one protease inhibitor. In G1 and G2, 53.2% and 81.8% respectively were patients with an AIDS-defining disease. The T CD4+ lymphocyte count increased progressively up until the 24th week of treatment in all patients, while VL became undetectable in 68.1% of G1 and in 63.6% of G2. The study concluded that the evolutions of laboratory tests were similar in the two treatment groups and that both presented a favorable clinical evolution.